Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer

Clinical Breast Cancer

Volumn 3, Issue SUPPL. 1, 2002, Pages

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Anthracycline; Combination chemotherapy; Gemcitabine; Taxanes; Toxicity; Vinorelbine

Indexed keywords

CYTARABINE; CYTOTOXIC AGENT; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; NUCLEOSIDE DERIVATIVE; TAXANE DERIVATIVE; VINCA ALKALOID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MONOTHERAPY; NEUROTOXICITY; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0036076122     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.s.008     Document Type: Article

References (37)

1. Chemotherapy of breast cancer: A historical perspective
2. Treatment of breast cancer
3. Developments in chemotherapy of breast cancer
4. Risks and benefits of taxanes in breast and ovarian cancer
5. Review of recent trials of chemotherapy for advanced breast cancer: The taxanes
6. Docetaxel
7. The emerging role of paclitaxel in breast cancer therapy
8. Phase II study of gemcitabine in patients with metastatic breast cancer
9. Phase II activity of gemcitabine in advanced breast cancer
10. Vinorelbine: An overview
11. Current status of vinorelbine for breast cancer
12. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
13. Advanced breast cancer: A phase II trial with gemcitabine
14. Difluorodeoxycytidine (gemcitabine): A phase II study in patients with advanced breast cancer
15. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
16. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older
17. Vinorelbine (navelbine): A third-generation vinca alkaloid
18. In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence
19. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules
20. Phase-II study of navelbine in advanced breast cancer
21. Vinorelbine (navelbine) in the treatment of breast cancer: The European experience
22. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy
23. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy
24. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma
25. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience
26. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study
27. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer
28. A phase I-II study of navelbine by 96 hours continuous infusion in metastatic breast cancer
29. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer
30. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer
31. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer
32. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
33. Dose-finding study of gemcitabine (G) plus vinorelbine (V) in metastatic breast cancer (MBC)
34. A phase II study of gemcitabine (G) and vinorelbine (V) in patients with advanced breast cancer (ABC)
35. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor
36. Gemcitabine and vinorelbine in pretreated advanced breast cancer: A pilot study
37. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group